Retatrutide
Triple receptor agonist studied in obesity and type 2 diabetes.
Search names: Reta, LY3437943
Evidence
Human · phase 2, 2023
Describes the linked sources, not an overall score for product quality or effectiveness.Half-life
Statistics reference: About 6 days
Human information in catalogueContext and sources for the statistics reference
From early human trials according to the catalogue.
About 6 days · Catalogue information from PeptideTracker.ai; read the limitation above. PeptideTracker.ai · Retatrutide ↗
Half-life, duration of effect and shelf life are different measures. Catalogue values may differ between variants and administration routes. Curves continue to use their stated statistics reference.
Adverse effects and limitations
Gastrointestinal adverse effects occur in the linked trials. See the specific source for study arm, frequency and other events.
Sources and further reading
Vital · user-supplied screen recordings, 1 Nov 2026
Study / medicine dataRetatrutide · randomized phase 2 trial↗Find researchPubMed · Retatrutide↗Research information, not a personal dosing plan. Last reviewed: 2026-11-01.